Loading...
NPI 1215921549 · Plainview, NY · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Acupath Laboratories, Inc. is a clinical medical laboratory provider located in Plainview, New York. This profile covers 34 Medicare and 31 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Acupath Laboratories, Inc. |
| Address | 28 S Terminal Dr |
| City | Plainview |
| State | NY |
| ZIP | 11803 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | September 1, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $14.8M |
| Medicare | $6.5M |
ACUPATH LABORATORIES, INC. presents as a high-volume pathology and clinical laboratory operation: its top Medicare and Medicaid revenue drivers are surgical pathology and staining/interpretive codes (88305, 88312, 88313, 88342) alongside molecular/COVID testing codes (U0003, U0005) and specialized cytogenetic probes (88121). The mix of codes indicates the business is principally providing histopathology and immunohistochemistry services with ancillary cytology and molecular testing rather than general ambulatory lab panels.
Medicare revenue is heavily concentrated in a few histopathology services: the precomputed top three Medicare codes account for 61.5% of Medicare revenue, with 88312 ($1.4M), 88305 ($1.3M), and 88313 ($1.2M) each representing large single-code contributions. That concentration signals the provider’s Medicare footprint is driven by a narrow set of high-volume pathology procedures rather than broad, diffuse Medicare lab testing.
Medicaid billing shows a similar concentration in a small set of services: the precomputed top three Medicaid codes account for 60.6% of Medicaid revenue, led by 88305 ($4.2M), U0003 ($2.6M), and 88342 ($2.2M). This indicates Medicaid revenue is dominated by both surgical pathology/IHC activity and substantial high-throughput infectious-agent testing.
Payer mix skews strongly toward Medicaid: reported Medicaid revenue is $14.8M while Medicare revenue is $6.5M, so Medicaid represents the larger source of payer dollars on file. That asymmetric mix implies operational exposure and contracting priorities will be different across payers, with Medicaid relationships and pricing likely more material to the business.
National competitive standing on surgical-pathology and staining codes is outsized: for Medicare ACUPATH ranks as an “extreme outlier” on multiple codes (88312 ranks #6 of 6966, 88313 ranks #3 of 6757, 88342 ranks #5 of 11370 and 88305 ranks #32 of 14580, all 100th percentile labels were reported). Those placements denote nationally uncommon volumes for these specialized pathology services and position the provider as a major national performer for those CPTs.
State-level dominance in New York Medicaid is pronounced for core pathology services: 88342, 88312, and 88313 each rank #1 in-state and 88305 ranks #2 of 642 (100th percentile labels for these codes were reported). This pattern demonstrates the provider is a leading in-state source for surgical pathology, special stains, and IHC, which has implications for local network negotiations and referral flows.
The provider shows a sizable Medicaid COVID/molecular testing footprint: U0003 accounts for 49.3K Medicaid claims and $2.6M (17.3% of Medicaid revenue) and ranks #25 of 336 in-state (93rd percentile), whereas Medicare U0003 activity is much smaller (1.2K claims, $87.2K, 1.4% of Medicare revenue). These figures indicate high-throughput infectious-agent testing is a material Medicaid line and a secondary, much smaller component for Medicare.
ACUPATH has long tenure in the NPI registry (enumerated 2005-09-01, ~21 years ago), and the reported payer revenues ($6.5M Medicare; $14.8M Medicaid) combined with repeated high-percentile rank statements support the conclusion that this is an established, specialized pathology laboratory with persistent high-volume activity in a limited set of diagnostic services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
34 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 88312 | The lab analyst performs the technical lab steps to stain a specimen with a special stain. This code applies to Group I for microorganisms. A qualified provider, typically a pathologist, interprets… | 16,730 | $80 | $1.4M |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 34,350 | $40 | $1.3M |
| 88313 | The lab analyst performs the technical lab steps to stain a specimen for Group II identification, for example an iron stain or trichrome stain. A qualified provider, typically a pathologist,… | 18,170 | $70 | $1.2M |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 16,040 | $70 | $1.1M |
| 88121 | The lab analyst performs a technical lab test on a urinary tract specimen using in situ hybridization and three to five molecular probes for computer assisted morphometric analysis, looking at the… | 1,040 | $380 | $392.7K |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 2,630 | $60 | $165.4K |
| 88360 | The lab analyst applies a single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist, evaluates the… | 1,680 | $100 | $160.8K |
| 88173 | The lab analyst performs the technical lab test to analyze a cytopathology specimen from a fine needle aspirate and then interprets and reports the results. | 640 | $150 | $94.5K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1,180 | $70 | $87.2K |
| 88112 | Selective cellular enhancement for cytopathology, such as the method of using a liquid–based slide preparation, uses a liquid–based medium to collect samples and preserve cells which can aid in… | 1,600 | $50 | $81.7K |
Showing 1–10 of 34
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 34 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
34 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87798 | 33 | 40 | 740 | $30 | $218.3K |
| 88120 | 12 | 30 | 90 | $450 | $133.6K |
| 88185 | 44 | 100 | 1,210 | $20 | $74.9K |
| 88305 | 5 | 980 | 370 | $50 | $58.5K |
| 87636 | 4 | 180 | 20 | $140 | $54.9K |
| 88377 | 10 | 50 | 50 | $210 | $50.8K |
| 87481 | 26 | 40 | 80 | $30 | $45.5K |
| 88121 | 1 | 10 | 40 | $260 | $42.5K |
| 87640 | 20 | 20 | 70 | $30 | $28K |
| 88312 | 1 | 430 | 70 | $70 | $24.6K |
Showing 1–10 of 34
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
31 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 78,940 | $50 | $4.2M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 49,320 | $50 | $2.6M |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 47,060 | $50 | $2.2M |
| 88312 | The lab analyst performs the technical lab steps to stain a specimen with a special stain. This code applies to Group I for microorganisms. A qualified provider, typically a pathologist, interprets… | 38,150 | $50 | $2M |
| 88313 | The lab analyst performs the technical lab steps to stain a specimen for Group II identification, for example an iron stain or trichrome stain. A qualified provider, typically a pathologist,… | 45,910 | $40 | $1.7M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 37,990 | $10 | $493.9K |
| 88121 | The lab analyst performs a technical lab test on a urinary tract specimen using in situ hybridization and three to five molecular probes for computer assisted morphometric analysis, looking at the… | 3,530 | $120 | $405.6K |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 7,430 | $40 | $319.5K |
| 88112 | Selective cellular enhancement for cytopathology, such as the method of using a liquid–based slide preparation, uses a liquid–based medium to collect samples and preserve cells which can aid in… | 8,200 | $20 | $172.2K |
| 88120 | The lab analyst performs a technical lab test on a urinary tract specimen using in situ hybridization and three to five molecular probes for manual morphometric analysis, looking at the number and… | 650 | $170 | $110K |
Showing 1–10 of 31
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
31 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 25 | 340 | 1,090 | $70 | $1.4M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 25 | 300 | 1,710 | $20 | $458.6K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 2 | 640 | 1,080 | $60 | $251.5K |
| 88120 | The lab analyst performs a technical lab test on a urinary tract specimen using in situ hybridization and three to five molecular probes for manual morphometric analysis, looking at the number and… | 8 | 20 | 380 | $210 | $232.6K |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 21 | 40 | 480 | $200 | $223.6K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 160 | 190 | 490 | $70 | $139.9K |
| 88312 | The lab analyst performs the technical lab steps to stain a specimen with a special stain. This code applies to Group I for microorganisms. A qualified provider, typically a pathologist, interprets… | 1 | 260 | 310 | $80 | $112.4K |
| 88377 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a… | 3 | 10 | 210 | $260 | $105.9K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 43 | 220 | 230 | $70 | $104.3K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 382 | 940 | 220 | $30 | $89.4K |
Showing 1–10 of 31
Other providers in the same ZIP code as Acupath Laboratories, Inc., ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Mid Island Therapy Associates, LLC D/b/a All About Kids | NY | Developmentally Disabled Services Day Training Agency | $0 | $26.9M |
| Central Nassau Guidance & Counseling Services, Inc. | NY | Mental Illness Community Based Residential Treatment Facility | $0 | $26M |
| Renal Focus Asc LLC | NY | Ambulatory Surgical Clinic/Center | $4.2M | $79.6K |
| Bijan Setareh-shenas | NY | Dermatology Physician | $1.4M | $2.8M |
| Peter Brennen | NY | Retina Specialist (Ophthalmology) Physician | $3M | $339.3K |
| Mehran Saboori | NY | Radiation Oncology Physician | $1.5M | $0 |
| Shawn Zimberg | NY | Radiation Oncology Physician | $1.1M | $0 |
| Mohsen Pahlavan | NY | Nephrology Physician | $768.8K | $305K |
| Prem Chatpar | NY | Rheumatology Physician | $939.3K | $5.3K |
| Robert Luntz | NY | Urology Physician | $758.3K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.